In vivo occupation of dopamine D1, D2 and serotonin (5-HT)2A receptors by sertindole in the rat brain

被引:0
作者
Takahashi, Y
Kusumi, I
Ishikane, T
Matsubara, S
Koyama, T
机构
[1] Hokkaido Univ, Sch Med, Dept Psychiat, Kita Ku, Sapporo, Hokkaido 0608638, Japan
[2] Int Med Ctr Japan, Dept Psychiat, Tokyo, Japan
[3] Tokachi Natl Med Hosp, Otofuke, Japan
来源
JOURNAL OF PSYCHIATRY & NEUROSCIENCE | 1998年 / 23卷 / 03期
关键词
antipsychotic agents; brain; rats; Wistar; receptors; dopamine D1; dopamine D2; serotonin;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: To determine the in vivo occupation of dopamine D-1, D-2 and serotonin (5-MT)(2A) receptors by novel antipsychotic agent sertindole using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), an irreversible antagonist at these receptor sites. Design: Animal study. interventions: Intraperitoneal administration to Wistar rats of I of 4 test compounds: a control compound of 0.15% tartaric acid, or a compound of either sertindole (0.5 mg/kg or 2.0 mg/kg) or clozapine (20 mg/kg) dissolved in 0.15% tartaric acid I hour before intraperitoneal administration of EEDQ (0 mg/kg) or ethanol/water solution. Results: Sertindole exhibited little or no effect on D and D, binding sites in vivo. On the other hand, sertindole occupied 5-HT2A receptors more extensively and firmly than EEDQ. This study indicates that sertindole is characterized by high occupancy of 5-HT2A receptors and by low or minimum occupancy of D-1 and D-2 receptors. Conclusions: These characteristics are very similar to atypical antipsychotic agents such as clozapine. Sertindole's low liability to cause extrapyramidal side effects (EPS) may be related to greater long-term binding for 5-HT2A receptors relative to D-2 receptors.
引用
收藏
页码:157 / 162
页数:6
相关论文
共 50 条
  • [1] Iron deficiency decreases dopamine D1 and D2 receptors in rat brain
    Erikson, KM
    Jones, BC
    Hess, EJ
    Zhang, Q
    Beard, JL
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2001, 69 (3-4) : 409 - 418
  • [2] Hetero-dimerization of serotonin 5-HT2A and dopamine D2 receptors
    Lukasiewicz, Sylwia
    Polit, Agnieszka
    Kendracka-Krok, Sylwia
    Wedzony, Krzysztof
    Mackowiak, Marzena
    Dziedzicka-Wasylewska, Marta
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2010, 1803 (12): : 1347 - 1358
  • [3] In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors
    Fenu, Sandro
    Espa, Elena
    Pisanu, Augusta
    Di Chiara, Gaetano
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 788 : 183 - 191
  • [4] Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D2 and 5-HT1A receptors
    Clinckers, R
    Smolders, I
    Meurs, A
    Ebinger, G
    Michotte, Y
    JOURNAL OF NEUROCHEMISTRY, 2004, 89 (04) : 834 - 843
  • [5] The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors
    W. Zhang
    F. P. Bymaster
    Psychopharmacology, 1999, 141 : 267 - 278
  • [6] The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors
    Zhang, W
    Bymaster, FP
    PSYCHOPHARMACOLOGY, 1999, 141 (03) : 267 - 278
  • [7] Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT2A and dopamine D2 receptors in rat prefrontal cortex
    Franklin, Jade M.
    Carrasco, Gonzalo A.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (10) : 1333 - 1347
  • [8] COMPARISON OF THE DISTRIBUTIONS OF D1 AND D2 DOPAMINE RECEPTOR MESSENGER-RNAS IN RAT-BRAIN
    MEADORWOODRUFF, JH
    MANSOUR, A
    HEALY, DJ
    KUEHN, R
    ZHOU, QY
    BUNZOW, JR
    AKIL, H
    CIVELLI, O
    WATSON, SJ
    NEUROPSYCHOPHARMACOLOGY, 1991, 5 (04) : 231 - 242
  • [9] Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms
    Hasbi, Ahmed
    O'Dowd, Brian F.
    George, Susan R.
    CURRENT OPINION IN PHARMACOLOGY, 2010, 10 (01) : 93 - 99
  • [10] Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors
    A. Newman-Tancredi
    D. Cussac
    V. Audinot
    M. J. Millan
    Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 359 : 447 - 453